Dossier
Zealand Pharma
Coverage of Zealand Pharma in the Nexus archive.
- Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
Zealand Pharma's stock experienced its two worst days on record as market enthusiasm for one of its experimental drugs waned. Investors are now focusing on amylin-based medicines as a potential growth driver for the company.
- Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
Zealand Pharma's shares fell in Copenhagen after the company reported that 20% of users discontinued its weight-loss drug due to gastrointestinal issues.